Dr. Lal Pathlabs Profile
Key Indicators
- Authorised Capital ₹ 107.96 Cr
- Paid Up Capital ₹ 83.58 Cr
- Company Age 30 Year, 8 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 475.06 Cr
- Satisfied Charges ₹ 93.80 Cr
- Revenue Growth -5.72%
- Profit Growth -15.03%
- Ebitda -9.70%
- Net Worth 14.45%
- Total Assets 4.80%
About Dr. Lal Pathlabs
Dr. Lal Pathlabs Limited (DLPL) is a leading Public Limited Indian Non-Government Company incorporated in India on 14 February 1995 and has a history of 30 years. Its registered office is in Delhi, India.
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 539524 and on the National Stock Exchange(NSE) under LALPATHLAB.
The Corporate was formerly known as Dr. Lal Pathlabs Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 107.96 Cr and a paid-up capital of Rs 83.58 Cr.
The company currently has active open charges totaling ₹475.06 Cr. The company has closed loans amounting to ₹93.80 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Dr. Lal Pathlabs Limited India are Ved Goel as Ceo, Vinay Gujral as Company Secretary, and Shankha Banerjee as Ceo. Rahul Sharma, Rajit Mehta, Om Manchanda, and Seven other members serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
- Apps
Corporate Identity Details
- CIN/LLPIN
L74899DL1995PLC065388
- Company No.
065388
- Stock Symbol
BSE : 539524 NSE : LALPATHLAB
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
14 Feb 1995
- Date of AGM
29 Jun 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Listed
- ROC Code
Roc Delhi
Industry
What products or services does Dr. Lal Pathlabs Limited offer?
Dr. Lal Pathlabs Limited offers a wide range of products and services, including Educational Services, Educational Consultants, Medical Educational Service, Medical Courses, Graduation & High Education Programs.
Who are the key members and board of directors at Dr. Lal Pathlabs?
Executive Team (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ved Goel  | CEO | 10-Aug-2018 | Current |
| Om Manchanda | Managing Director | 01-Feb-2011 | Current |
| Vinay Gujral | Company Secretary | 11-May-2023 | Current |
| Shankha Banerjee | CEO | 30-May-2024 | Current |
Board Members (9)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Somya Satsangi  | Director | 08-Feb-2019 | Current |
| Rahul Sharma | Director | 22-Jul-2005 | Current |
| Arvind Lal | Whole-Time Director | 14-Feb-1995 | Current |
Arun Duggal  | Director | 21-Aug-2015 | Current |
| Rajit Mehta | Director | 27-Jul-2023 | Current |
| Archana Erdmann | Director | 17-May-2019 | Current |
Financial Performance of Dr. Lal Pathlabs.
Dr. Lal Pathlabs Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 5.72% decrease. The company also saw a substantial fall in profitability, with a 15.03% decrease in profit. The company's net worth Soared by an impressive increase of 14.45%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dr. Lal Pathlabs?
In 2021, Dr. Lal Pathlabs had a promoter holding of 55.23% and a public holding of 44.77%. The company had 8 Subsidiaries. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Windows Consultants Private LimitedRajit Mehta is a mutual person
J B Chemicals And Pharmaceuticals LimitedArun Duggal is a mutual person
Ask Automotive LimitedArun Duggal is a mutual person
Tlgs Consulting Group Private LimitedSomya Satsangi is a mutual person
Association Of Senior Living IndiaRajit Mehta is a mutual person
Chimes Aviation Private LimitedRahul Sharma is a mutual person
Charges (Loans)
₹475.06 Cr
₹93.80 Cr
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 250.00 Cr
- Axis Bank Limited : 185.00 Cr
- Others : 40.00 Cr
- State Bank Of Baroda : 0.06 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 24 Jun 2022 | Hdfc Bank Limited | ₹250.00 Cr | Open |
| 10 Nov 2021 | Others | ₹40.00 Cr | Open |
| 09 Nov 2021 | Axis Bank Limited | ₹185.00 Cr | Open |
| 19 Apr 1988 | State Bank Of Baroda | ₹0.61 M | Open |
| 07 Dec 2020 | Others | ₹10.00 Cr | Satisfied |
How Many Employees Work at Dr. Lal Pathlabs?
Dr. Lal Pathlabs has a workforce of 4081 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dr. Lal Pathlabs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dr. Lal Pathlabs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
